Aurinia Pharmaceuticals Company Profile (TSE:ISA)

About Aurinia Pharmaceuticals (TSE:ISA)

Aurinia Pharmaceuticals logoAurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: TSE:ISA
  • CUSIP: N/A
  • Web:
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
  • Dividend Yield: 1.0%
  • Net Margins: -729.18%
  • Return on Equity: -5.48%
  • Return on Assets: -4.50%

Frequently Asked Questions for Aurinia Pharmaceuticals (TSE:ISA)

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the Tornton Stock Exchange (TSX) under the ticker symbol "ISA."

Who are some of Aurinia Pharmaceuticals' key competitors?

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:

  • Richard M. Glickman LL.D., Executive Chairman of the Board, Chief Executive Officer
  • Dennis Bourgeault, Chief Financial Officer, Corporate Secretary
  • Michael R. Martin, Chief Operating Officer
  • Neil Solomons M.D., Chief Marketing Officer
  • Celia Economides, Associate Vice President, Corporate Communications & Patient Advocacy
  • Robert B. Huizinga, Vice President - Clinical Affairs
  • Lawrence D. Mandt, Vice President - Regulatory and Quality
  • George M. Milne Jr., Ph.D., Director
  • Lorin Jeffry Randall, Director
  • Benjamin Rovinski Ph.D., Independent Director

How do I buy Aurinia Pharmaceuticals stock?

Shares of Aurinia Pharmaceuticals and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE ISA)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aurinia Pharmaceuticals (TSE:ISA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Aurinia Pharmaceuticals (TSE:ISA)
Price Target History for Aurinia Pharmaceuticals (TSE:ISA)
Analysts' Ratings History for Aurinia Pharmaceuticals (TSE:ISA)
No equities research coverage for this company has been tracked by


Earnings History for Aurinia Pharmaceuticals (TSE:ISA)
No earnings announcements for this company have been tracked by


Earnings Estimates for Aurinia Pharmaceuticals (TSE:ISA)

No earnings estimates for this company have been tracked by


Dividend History for Aurinia Pharmaceuticals (TSE:ISA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Aurinia Pharmaceuticals (TSE:ISA)
No insider trades for this company have been tracked by


Headline Trends for Aurinia Pharmaceuticals (TSE:ISA)
Latest Headlines for Aurinia Pharmaceuticals (TSE:ISA)
DateHeadline logoAurinia's Path Forward - November 15 at 3:48 PM logoMid-Day Market Update: Aurinia Pharmaceuticals Gains On AURION Data; Twitter Shares Slide - October 6 at 1:20 PM logo16 Stocks Moving In Friday's Pre-Market Session - September 30 at 9:22 AM



Aurinia Pharmaceuticals (ISA) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.